J&J Doses Expected to Arrive in India in November-December, Zydus Cadila Next

After the Centre gave the foreign Covid-19 vaccine producer Emergency Use Authorization (EUA) last week, India is set to receive the first doses of Johnson & Johnson’s single-shot vaccine in November or December this year, according to a top government source.

After Covishield, Covaxin, and Sputnik, the government expects Zydus Cadila’s DNA vaccine, which may receive FDA approval soon, to be the next coronavirus vaccine to come. Zydus Cadila is expected to deliver two crore dosages per month, according to the source.

The vaccine from Biological E is also expected with an initial lot of seven crore doses in one go as the firm is doing at-risk production after the Centre extended it a Rs 1,500 crore advance. “The firm will soon apply for comparative studies and their data is good,” the source further said. Gennova’s vaccine is also expected in October.

The government source said that the priority right now was expanding the capacity of Bharat Biotech with its three plants becoming functional now. “In August, we will be getting three crore doses of Covaxin, which will go up to four crore in September and 6-7 crore from October,” the government source said, adding that Hyderabad-based firm Bharat Biotech had suffered as first batch of the manufacturer had failed.

Pune-based Serum Institute of India (SII) will supply nearly 15 crore doses of Covishield every month and is keen to start export of the vaccine. The government has told the SII that vaccinating Indians is a priority for now.

Meanwhile, the government is banking on only one crore doses of Russia’s Sputnik V vaccine in all as the local manufacturers are facing a trouble in producing the second dose of the vaccine, whose component is different from the first.

Regarding the approval of Covaxin by the World Health Organisation, the government source said a last dossier will go to the WHO in a couple of days and the WHO could soon call an expert committee meeting to give clearance.